IDEA AG - US Patent Office grants a new patent - Gilde Healthcare

IDEA AG – US Patent Office grants a new patent

4 februari 2009

Munich, Germany – IDEA AG today announced the granting of a new US patent (7,473,432) that covers the recently improved Transfersome® technology and the Company’s lead product, Diractin®, which is already approved in Switzerland and in the final stage (phase III) of clinical development in Europe and the USA.

The invention describes and claims new formulations of non-steroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates, the Transfersome® vesicles, with at least three amphiphatic components suspended in a suitable polar liquid.  The key characteristic of the aggregates is their ability to penetrate narrow hydrophilic pores in a semi-permeable barrier, such as the skin. This enables the Transfersome® carriers to transport NSAIDs through the skin barrier for improved local deposition and longer duration of drug action. The newly patented NSAID carriers moreover help to control the depth of drug delivery, by virtue of their special ability to bypass the sink of cutaneous blood capillaries. The carrier-mediated localized delivery of NSAIDs can consequently ameliorate therapy of diseased peripheral tissues below the site of administration, by supporting the beneficial action and minimizing the systemic side effects of such drugs.

The new patent also specifically covers Diractin® (ketoprofen in Transfersome® gel, formerly known as IDEA-033). It thus provides a valuable basis for future marketing of IDEA’s innovative targeted analgesic in the United States. In September 2007 IDEA has out-licensed the US right to a subsidiary of Alpharma Inc., which was recently acquired by King Pharmaceuticals Inc. The IP protection under this newly granted patent will last till June 2025.

Meer nieuws

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
17 oktober 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15 oktober 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
14 oktober 2025